Solid Biosciences Inc. (SLDB) financial statements (2022 and earlier)

Company profile

Business Address 141 PORTLAND STREET, FIFTH FLOOR
CAMBRIDGE, MA 02139
State of Incorp. DE
Fiscal Year End December 31
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments207,779154,74483,524122,464
Cash and cash equivalents119,136154,74476,04386,366
Short-term investments88,643 7,48136,098
Receivables110   
Other undisclosed current assets14,7234,1572,7786,175
Total current assets:222,612158,90186,302128,639
Noncurrent Assets
Operating lease, right-of-use asset1,1423,5794,988
Property, plant and equipment6,4628,15311,64510,422
Restricted cash and investments2,070327327327
Other noncurrent assets94209209209
Total noncurrent assets:9,76812,26817,16910,958
TOTAL ASSETS:232,380171,169103,471139,597
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities13,99111,91416,30211,926
Accounts payable4,4633,2747,1243,691
Accrued liabilities9,5288,6409,1788,235
Deferred revenue8,08010,359 
Debt2322081,922173
Other liabilities35 52382
Other undisclosed current liabilities1,2631,999  
Total current liabilities:23,60124,48018,27612,481
Noncurrent Liabilities
Long-term debt and lease obligation5682,9445,147859
Finance lease, liability293525733
Capital lease obligations859
Operating lease, liability2752,4194,414
Liabilities, other than long-term debt 11,659 1,074
Deferred revenue 10,359 
Other liabilities 1,300 1,074
Other undisclosed noncurrent liabilities(275)   
Total noncurrent liabilities:56814,6035,1471,933
Total liabilities:24,16939,08323,42314,414
Stockholders' equity
Stockholders' equity attributable to parent208,211132,08680,048125,183
Common stock112874835
Additional paid in capital684,901536,568396,278324,209
Accumulated other comprehensive income (loss)(45) 1(5)
Accumulated deficit(476,757)(404,569)(316,279)(199,056)
Total stockholders' equity:208,211132,08680,048125,183
TOTAL LIABILITIES AND EQUITY:232,380171,169103,471139,597

Income statement (P&L) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
Revenues13,620   
Gross profit:13,620   
Operating expenses(85,874)(88,406)(119,318)(75,687)
Operating loss:(72,254)(88,406)(119,318)(75,687)
Nonoperating income661162,095889
Investment income, nonoperating641151,580619
Other nonoperating income21515270
Net loss available to common stockholders, diluted:(72,188)(88,290)(117,223)(74,798)

Comprehensive Income ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
Net loss:(72,188)(88,290)(117,223)(74,798)
Other undisclosed comprehensive income (loss)(45)(1)68
Comprehensive loss, net of tax, attributable to parent:(72,233)(88,291)(117,217)(74,790)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: